Clinical trial

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir

NCT03374358

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Raltegravir Normalized identity: raltegravirView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-01-10

PhasePHASE4

Conditions

HIV Seropositivityunresolved

Metabolic Syndromeverified · MONDO: abdominal obesity-metabolic syndrome

Fatty Liververified · MONDO: fatty liver disease

Interventions

RaltegravirDRUG · verified · RxNorm: raltegravir

Sponsors & collaborators

Helsinki University Central Hospitallead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

HelsinkiFinland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03374358 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.